CRL (Charles River Laboratories International) Debt-to-Equity : 0.79 (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Charles River Laboratories International Debt-to-Equity?

Charles River Laboratories International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0 Mil. Charles River Laboratories International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $2,724 Mil. Charles River Laboratories International's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $3,462 Mil. Charles River Laboratories International's debt to equity for the quarter that ended in Dec. 2024 was 0.79.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Charles River Laboratories International's Debt-to-Equity or its related term are showing as below:

CRL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.79 Med: 1.12 Max: 1.48
Current: 0.79

During the past 13 years, the highest Debt-to-Equity Ratio of Charles River Laboratories International was 1.48. The lowest was 0.79. And the median was 1.12.

CRL's Debt-to-Equity is ranked worse than
79.69% of 192 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs CRL: 0.79

Charles River Laboratories International Debt-to-Equity Historical Data

The historical data trend for Charles River Laboratories International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Charles River Laboratories International Debt-to-Equity Chart

Charles River Laboratories International Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

1.02

1.15

1.04

0.85

0.79

Charles River Laboratories International Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.85	0.85	0.76	0.73	0.79

Competitive Comparison of Charles River Laboratories International's Debt-to-Equity

For the Diagnostics & Research subindustry, Charles River Laboratories International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Charles River Laboratories International's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Charles River Laboratories International's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Charles River Laboratories International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Charles River Laboratories International's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	2723.994)	/	3461.503
	=	0.79

Charles River Laboratories International's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	2723.994)	/	3461.503
	=	0.79

Charles River Laboratories International (NYSE:CRL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Charles River Laboratories International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Charles River Laboratories International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Charles River Laboratories International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Charles River Laboratories International Inc (NYSE:CRL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RV6:Germany RV6:Germany

Address

251 Ballardvale Street, Wilmington, MA, USA, 01887

Website

https://www.criver.com

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Executives

Birgit Girshick	officer: Corporate Executive VP	251 BALLARDVALE STREET, WILMINGTON MA 01887
Joseph W Laplume	officer: EVP, Corp Strategy & Develop	251 BALLARDVALE STREET, WILMINGTON MA 01887
James C Foster	director, officer: President and CEO	251 BALLARDVALE ST, WILMINGTON MA 01887
Richard F Wallman	director	HONEYWELL, 101 COLUMBIA ROAD, MORRISTOWN NJ 07962
George Massaro	director
Michael Gunnar Knell	officer: CSVP&Chief Accounting Officer	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Victoria L Creamer	officer: EVP & Chief People Officer	164 PINE HILL ROAD, NEW FAIRFIELD CT 06812
William D Barbo	officer: Corporate Executive VP & CCO	251 BALLARDVALE STREET, WILMINGTON MA 01887
Shannon M Parisotto	officer: CEVP, Disc & Safety Assessment	251 BALLARDVALE ST, WILMINGTON MA 01887
Flavia Pease	officer: Corporate Executive VP	251 BALLARDVALE STREET, WILMINGTON MA 01887
David Ross Smith	officer: Corporate Executive VP & CFO	251 BALLARDVALE STREET, WILMINGTON MA 01887
Deborah Turner Kochevar	director	251 BALLARDVALE STREET, WILMINGTON MA 01887
Milne George M Jr	director
Stephen D Chubb	director	C/O MATRITECH INC, 330 NEVADA STREET, NEWTON MA 02460
George Llado	director	251 BALLARDVALE STREET, WILMINGTON MA 01887